Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBC...

The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) result...

ALT: a green bay packers football player with the number 52 on his uniform

Key Points. Air pollution exposure is common, and may increase risk of developing blood clots.Greater long-term exposure to air pollution (i.e., PM2.5, NOx

PURPOSEWe conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphom...

Key Points. Glofitamab shows a 47% overall response rate (27% CR, 20% PR) and manageable safety in heavily pretreated r/r LBCL patients.Increased LDH is th

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a...

ALT: a green bay packers player wearing a helmet with the letter c on it

Key Points. Axi-cel and liso-cel had similar outcomes, though when accounting for differences in risk factors, axi-cel was associated with superior PFS.We

Key Points. Three-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomesManagea

Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024

ALT: a green background with a hand holding a flag and the words go go go